Gadolinium-based contrast drugs being reviewed by FDA

by Administrator 13. October 2009 00:19

The FDA has released its list of drugs that are being reviewed for safety problems. These drugs include gadolinium-based contrast agents, which are used during magnetic resonance imaging.

The FDA is investigating these drugs for potential links to anaphylaxis hypersensitivity. The drugs have already been linked to Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy.

If you or anyone you know has received a gadolinium-based contrast agent, contact the NSF and NFD lawyers of Williams Kherkher at 800-761-3187.

Be the first to rate this post

Currently 0/5 Stars.
1
2
3
4
5

Tags:

NFD attorney | NFD lawyers | NSF attorneys

FDA Approves Application for New Gadolinium-Based MRI Contrast AgentA German pharmaceutical company announced the United States Food and Drug Administration has accepte...Diagnosed with Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD) after and MRI There is updated information from the Food and Drug Administration (FDA) for patients who have und...Gadolinium-based Contrast AgentsThe U.S. Food and Drug Administration (FDA) first notified health care professionals and the public ...

home | about the firm | attorneys | nsf/nsd | gadolinium | articles | contact us | blog | resources | link exchange
© Copyright 2004-2010 Williams Kherkher. Attorneys are licensed only in the state of Texas unless otherwise indicated in the biographical section. Past performance is no guarantee of future results. Williams Kherkher's primary office is located in Texas. Terms of Use. Disclaimer.
8441 Gulf Freeway, Suite 600, Houston, TX 77017-5051 -- 800-696-5341

Search Engine Optimization provided by The Search Engine Guys.

Gadolinium-based contrast drugs being reviewed by FDA

Related posts

Month List

Gadolinium-based contrast drugs being reviewed by FDA

Related posts

Month List

BlogRoll

Category list